R-209 is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase I drugs for Inflammatory Bowel Disease have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how R-209’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
R-209 is under development for the treatment of inflammatory bowel disease.
Douglas Pharmaceuticals overview
Douglas Pharmaceuticals (Douglas) is a pharmaceutical company that develops and manufactures pharmaceutical and nutraceutical products. It offers consumer, prescription and automation products. The company’s consumer products include supplements and multivitamins, creams and skincare and others. Its automation products provide dispensing machines, small machines and accessories. Douglas also provides contract manufacturing services, clinical trials and laboratory services and internship programs. The company offers products in various therapeutic areas including analgesic, anti-allergy, anti-inflammatory, anti-viral, anti-fungal, anti-fungal, cardiovascular, dermatology, mental health and neonatal. It markets its products under the brands Phloe, Prospan, Cognizin, LactoSpore, Tolerase, GastroEzy, MobiJoint and Peaceful Dreams. The company collaborates with universities, researchers and clinicians. Douglas is headquartered in Auckland, New Zealand.
For a complete picture of R-209’s drug-specific PTSR and LoA scores, buy the report here.